Delivery of erythropoietin by encapsulated myoblasts in a genetic model of severe anemia

Kidney International

Volumn 62, Issue 4, 2002, Pages 1395-1401

  Rinsch, Christopher ^a,b,c   Dupraz, Phillipe ^a,b,c   Schneider, Bernard L ^a,b,c   Déglon, Nicole ^a,b,c   Maxwell, Patrick H ^a,b,c   Ratcliffe, Peter J ^a,b,c   Aebischer, Patrick ^a,b,c  

^a Modex Therapeutiques   (Switzerland)

^b EPFL   (Switzerland)

^c Henry Wellcome Building of Genomic Medicine ^*  (United Kingdom)

Author keywords

Anemia; Chronic renal failure; Encapsulation; Gene therapy; Hematocrit; Hemopoiesis; Immunosuppression; Transplantation

Indexed keywords

ERYTHROPOIETIN; MONOCLONAL ANTIBODY;

ALLELE; ANEMIA; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ENCAPSULATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; GENE THERAPY; GENETIC ENGINEERING; HEMATOCRIT; HEMATOPOIESIS; HOMOZYGOSITY; IMMUNE RESPONSE; MEASUREMENT; MOUSE; MYOBLAST; NONHUMAN; PRIORITY JOURNAL;

EID: 0036378210     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2002.00574.x     Document Type: Article

References (13)

1. JELKMANN W: Erythropoietin: Structure, control of production, and function. Physiol Rev 72:449-489, 1992
2. OSBORNE WR, RAMESH N, LAU S, et al: Gene therapy for long-term expression of erythropoietin in rats. Proc Natl Acad Sci USA 92:8055-8058, 1995
3. NAFFAKH N, HENRI A, VILLEVAL JL, et al: Sustained delivery of erythropoietin in mice by genetically modified skin fibroblasts. Proc Natl Acad Sci USA 92:3194-3198, 1995
4. SVENSSON EC, BLACK HB, DUGGER DL, et al: Long-term erythropoietin expression in rodents and non-human primates following intramuscular injection of a replication-defective adenoviral vector. Hum Gene Ther 8:1797-1806, 1997
5. REGULIER E, SCHNEIDER BL, DEGLON N, et al: Continuous delivery of human and mouse erythropoietin in mice by genetically engineered polymer encapsulated myoblasts. Gene Ther 5:1014-1022, 1998
6. HAMAMORI Y, SAMAL B, TIAN J, KEDES L: Myoblast transfer of human erythropoietin gene in a mouse model of renal failure. J Clin Invest 95:1808-1813, 1995
7. MAXWELL PH, OSMOND MK, PUGH CW, et al: Identification of the renal erythropoietin-producing cells using transgenic mice. Kidney Int 44:1149-1162, 1993
8. RAJA KB, MAXWELL PH, RATCLIFFE PJ, et al: Iron metabolism in transgenic mice with hypoplastic anaemia due to incomplete deficiency of erythropoietin. Br J Haematol 96:248-253, 1997
9. RINSCH C, REGULIER E, DEGLON N, et al: A gene therapy approach to regulated delivery of erythropoietin as a function of oxygen tension. Hum Gene Ther 8:1881-1889, 1997
10. DUPRAZ P, RINSCH C, PRALONG WF, et al: Lentivirus-mediated Bcl-2 expression in betaTC-tet cells improves resistance to hypoxia and cytokine-induced apoptosis while preserving in vitro and in vivo control of insulin secretion. Gene Ther 6:1160-1169, 1999
11. POTTER MA, HYMUS S, STOCKLEY T, CHANG PL: Suppression of immunological response against a transgene product delivered from microencapsulated cells. Hum Gene Ther 9:1275-1282, 1998
12. ROBERTS HR, EBERST ME: Current management of hemophilia B. Hematol Oncol Clin North Am 7:1269-1280, 1993
13. TRIPATHY SK, BLACK HB, GOLDWASSER E, LEIDEN JM: Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat Med 2:545-550, 1996